Table 2. Non-functional adrenal tumors and the risk of developing incident outcomes.
The table shows the results of adjusted regression models to evaluate the risk for developing incident outcomes in participants with NFAT when compared to participants without any adrenal tumors.
| Incident Outcomes | Hypertension | Hyper-lipidemia | Composite Diabetes | Pre-Diabetes | Type 2 Diabetes | Chronic Kidney Disease | Cardio-Vascular Events |
|---|---|---|---|---|---|---|---|
| Number of Incident Events† Among Eligible Participants with NFAT+ | 19/74 (25.7%) | 15/87 (17.2%) | 30/110 (27.3%) | 23/110 (20.9%) | 14/126 (11.1%) | 15/152 (9.9%) | 13/138 (9.4%) |
| Person-years at risk | 519 | 617 | 807 | 807 | 902 | 1,104 | 1,019 |
|
| |||||||
| Number of Incident Events† Among Eligible Participants with no Adrenal Tumor | 125/400 (31.3%) | 66/461 (14.3%) | 72/615 (11.7%) | 36/615 (5.8) | 44/646 (6.8%) | 62/715 (8.7%) | 55/629 (8.7%) |
| Person-years at risk | 3,318 | 3,687 | 4,946 | 4,946 | 5,161 | 5,651 | 5,031 |
|
| |||||||
| Unadjusted Risk Ratios [95%CI] | 0.82 [0.51, 1.33] | 1.20 [0.69, 2.11] | 2.33 [1.52, 3.57] | 3.57 [2.12, 6.03] | 1.63 [0.89, 2.98] | 1.14 [0.65, 2.00] | 1.08 [0.59, 1.97] |
| Unadjusted Rate Ratios [95%CI] | 0.97 [0.56, 1.58] | 1.35 [0.72, 2.40] | 2.55 [1.61, 3.96] | 3.91 [2.21, 6.79] | 1.82 [0.92, 3.38] | 1.23 [0.65, 2.20] | 1.16 [0.59, 2.16] |
|
| |||||||
| Multivariable Model 1 Risk Ratios [95%CI]* | 0.83 [0.51, 1.35] | 1.06 [0.58, 1.92] | 2.09 [1.33, 3.27] | 3.34 [1.93, 5.80] | 1.54 [0.81, 2.92] | 1.10 [0.59, 2.05] | 0.94 [0.49, 1.78] |
| Multivariable Model 1 Rate Ratios [95%CI]* | 0.95 [0.58, 1.55] | 1.17 [0.64, 2.13] | 2.26 [1.44, 3.54] | 3.64 [2.10, 6.31] | 1.71 [0.90, 3.25] | 1.19 [0.64, 2.24] | 0.97 [0.50, 1.85] |
|
| |||||||
| Multivariable Model 2 Risk Ratios [95%CI]** | 0.76 [0.46, 1.26] | 1.03 [0.55, 1.91] | 2.03 [1.29, 3.19] | 3.26 [1.87, 5.69] | 1.50 [0.79, 2.87] | 0.99 [0.52, 1.86] | 0.78 [0.41, 1.50] |
| Multivariable Model 2 Rate Ratios [95%CI]** | 0.85 [0.51, 1.41] | 1.10 [0.59, 2.05] | 2.17 [1.37, 3.42] | 3.59 [2.05, .6.28] | 1.63 [0.85, 3.14] | 1.15 [0.60, 2.16] | 0.76 [0.39, 1.49] |
|
| |||||||
| Multivariable Model 3 Risk Ratios [95%CI]*** | 0.93 [0.55, 1.57] | 0.95 [0.51, 1.78] | 1.87 [1.17, 2.98] | 3.19 [1.83, 5.59] | 0.99 [0.49, 1.98] | 1.00 [0.53, 1.89] | 0.72 [0.37, 1.39] |
| Multivariable Model 3 Rate Ratios [95%CI]*** | 1.03 [0.61, 1.72] | 1.04 [0.55, 1.95] | 1.98 [1.23, 3.17] | 3.56 [2.02, 6.25] | 1.10 [0.54, 2.24] | 1.12 [0.59, 2.14] | 0.69 [0.34, 1.37] |
Incident event is defined as not having the specific outcome at baseline assessment and developing the outcome during the follow-up time.
Eligible participants include those who did not have the outcome of interest at baseline and who had ≥ 3 years of follow-up data to assess the incident development of this outcome over time.
Incident events of composite diabetes do not add up to the sum of incident type 2 diabetes events and pre-diabetes events because 15 individuals who developed incident type 2 diabetes had a diagnosis of pre-diabetes at baseline.
Multivariable Model 1 includes adjustment for: age, BMI, gender, race, smoking status
Multivariable Model 2 includes adjustment for: Model 1 + other clinically relevant baseline cardiovascular and metabolic diagnoses (hypertension, composite diabetes, hyperlipidemia, cardiovascular events, chronic kidney disease).
Multivariable Model 3 includes adjustment for: Model 2 + use of anti-hypertensive medications, use of anti-diabetes medications (oral hypoglycemics and insulin), and use of medications to treat coronary artery disease or hyperlipidemia (anti-platelets, nitrates, statins, fibrates, niacin).
NFAT= “non-functional” adrenal tumor